In early October, DiaMedica has announced the preliminary results of its Phase II human study with DM-71, which demonstrated the ability of DM-71 to reduce HbA1c when compared to baseline, as well as demonstrating safety and tolerability of the drug. In September, the company announced that preclinical studies had demonstrated the ability of DM-83 to restore insulin sensitivity to pre-diabetic levels.
Karl-Gunnar Hidinger, president of DiaMedica, said: “As we prepare for the next stage of human clinical development with DM-71, it is our goal to complete proof-of-concept Phase II human studies with DM-83 and DM-99 as expeditiously as possible, beginning with DM-83. The European Union is recognized as an excellent environment for conducting clinical studies, and our European entity has been established as part of our strategy to move products into the clinic rapidly.”